☰

Mark Chao, MD, PhD - Publications

Affiliations: 
2008-2017 Stanford University, Palo Alto, CA 
 2016- Forty Seven, Inc. 
Tree Info Similar researchers PubMed Report error

48 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Finotti G, Pietronigro E, Balanzin C, Lonardi S, Constantin G, Chao MP, Tecchio C, Vermi W, Cassatella MA. slan+ monocytes kill cancer cells coated in therapeutic antibody by trogoptosis. Cancer Immunology Research. PMID 37695535 DOI: 10.1158/2326-6066.CIR-23-0239  0.523
2023 Kotini AG, Carcamo S, Cruz-Rodriguez N, Olszewska M, Wang T, Demircioglu D, Chang CJ, Bernard E, Chao MP, Majeti R, Luo H, Kharas MG, Hasson D, Papapetrou EP. Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia. Blood Cancer Discovery. OF1-OF18. PMID 37067914 DOI: 10.1158/2643-3230.BCD-22-0167  0.583
2022 Chen J, Johnson L, McKenna K, Choi T, Duan J, Feng D, Tsai J, Garcia-Martin N, Sompalli K, Maute R, Vyas P, Majeti R, Takimoto C, Liu J, Ramsingh G, ... Chao M, et al. MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS). Clinical Lymphoma, Myeloma & Leukemia. S317-S318. PMID 36163968 DOI: 10.1016/S2152-2650(22)01421-5  0.725
2022 Sallman D, Malki MA, Asch A, Wang E, Jurcic J, Bradley T, Flinn I, Pollyea D, Kambhampati S, Tanaka T, Zeidner J, Garcia-Manero G, Jeyakumar D, Gu L, Tan A, ... Chao M, et al. MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results. Clinical Lymphoma, Myeloma & Leukemia. S314-S315. PMID 36163963 DOI: 10.1016/S2152-2650(22)01415-X  0.387
2022 Daver N, Vyas P, Kambhampati S, Malki MA, Larson R, Asch A, Mannis G, Chai-Ho W, Tanaka T, Bradley T, Jeyakumar D, Wang E, Xing G, Chao M, Ramsingh G, et al. AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results. Clinical Lymphoma, Myeloma & Leukemia. S253-S254. PMID 36163845 DOI: 10.1016/S2152-2650(22)01300-3  0.47
2022 Vyas P, Daver N, Chao M, Xing G, Renard C, Ramsingh G, Sallman D. AML-399 A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma & Leukemia. S247. PMID 36163834 DOI: 10.1016/S2152-2650(22)01288-5  0.359
2020 Lakhani NJ, Patnaik A, Liao JB, Moroney JW, Miller DS, Fleming GF, Axt M, Wang YV, Agoram B, Volkmer J, Maute R, Schroeder A, Chico I, Chao M, Takimoto CH, et al. A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients. Journal of Clinical Oncology. 38: 18-18. DOI: 10.1200/Jco.2020.38.5_Suppl.18  0.365
2020 Fisher GA, Lakhani NJ, Eng C, Hecht JR, Bendell JC, Philip PA, O'Dwyer PJ, Johnson B, Kardosh A, Ippolito TM, Wang YV, Agoram B, Volkmer J, Maute R, Chico I, ... Chao M, et al. A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients. Journal of Clinical Oncology. 38: 114-114. DOI: 10.1200/Jco.2020.38.4_Suppl.114  0.354
2020 Kiss B, Volkmer AK, Feng D, McKenna KM, Mihardja S, Chao M, Takimoto CH, Liao JC, Volkmer J, Weissman IL. Magrolimab and gemcitabine-cisplatin combination enhance phagocytic elimination of bladder cancer. Journal of Clinical Oncology. 38: e17035-e17035. DOI: 10.1200/Jco.2020.38.15_Suppl.E17035  0.544
2020 Agoram B, Jin C, Maute R, Takimoto CH, Chao M, Sallman DA. Pharmacokinetic (PK)-pharamcodynamic (PD) analysis and receptor occupancy data to support every other week maintenance dosing of magrolimab in combination with azacitidine in MDS/AML patients. Journal of Clinical Oncology. 38: e15098-e15098. DOI: 10.1200/Jco.2020.38.15_Suppl.E15098  0.412
2020 Sallman DA, Al Malki M, Asch AS, Lee DJ, Kambhampati S, Donnellan WB, Bradley TJ, Vyas P, Jeyakumar D, Marcucci G, Komrokji RS, Van Elk J, Lin M, Maute R, Volkmer J, ... ... Chao M, et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. Journal of Clinical Oncology. 38: 7507-7507. DOI: 10.1200/Jco.2020.38.15_Suppl.7507  0.398
2019 Chao MP, Takimoto CH, Feng DD, McKenna K, Gip P, Liu J, Volkmer JP, Weissman IL, Majeti R. Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies. Frontiers in Oncology. 9: 1380. PMID 32038992 DOI: 10.3389/Fonc.2019.01380  0.723
2019 Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, ... Chao MP, et al. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1802018. PMID 30811285 DOI: 10.1200/Jco.18.02018  0.7
2019 Advani R, Volkmer JP, Chao MP. CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma. The New England Journal of Medicine. 380: 497-498. PMID 30699313 DOI: 10.1056/NEJMc1816156#SA2  0.368
2019 Chao MP, Majeti R. Induced pluripotent stem cell modeling of malignant hematopoiesis. Experimental Hematology. PMID 30659850 DOI: 10.1016/J.Exphem.2019.01.002  0.551
2019 Sallman DA, Donnellan WB, Asch AS, Lee DJ, Malki MA, Marcucci G, Pollyea DA, Kambhampati S, Komrokji RS, Elk JV, Lin M, Agoram B, Chen JY, Volkmer J, Takimoto CHM, ... Chao M, et al. The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results. Journal of Clinical Oncology. 37: 7009-7009. DOI: 10.1200/Jco.2019.37.15_Suppl.7009  0.578
2019 Marjon KD, Chen JY, Duan J, Choi TS, Sompalli K, Feng D, Mata O, Chen S, Kean L, Chao MM, Chao M, Takimoto CH, Agoram B, Dunbar CE, Majeti R, et al. An All Antibody Approach for Conditioning Bone Marrow for Hematopoietic Stem Cell Transplantation with Anti-cKIT and Anti-CD47 in Non-Human Primates Blood. 134: 4428-4428. DOI: 10.1182/Blood-2019-131490  0.57
2019 Maute RL, Chen JY, Marjon KD, Duan J, Choi T, Chao M, Takimoto CH, Agoram B, Volkmer J. Translational Study of Cell Surface Proteins in Non-Hodgkin Lymphoma Patients Treated with the First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Rituximab Blood. 134: 5229-5229. DOI: 10.1182/Blood-2019-127526  0.562
2019 Sallman DA, Asch AS, Malki MMA, Lee DJ, Donnellan WB, Marcucci G, Kambhampati S, Daver NG, Garcia-Manero G, Komrokji RS, Elk JV, Lin M, Volkmer J, Takimoto CH, Chao M, et al. The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results Blood. 134: 569-569. DOI: 10.1182/Blood-2019-126271  0.482
2018 Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, ... ... Chao MP, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. The New England Journal of Medicine. 379: 1711-1721. PMID 30380386 DOI: 10.1056/Nejmoa1807315  0.703
2018 Advani RH, Flinn I, Popplewell L, Forero-Torres A, Bartlett NL, Ghosh N, Kline JP, Tran T, Lynn J, Chen JY, Agoram B, Huang J, Takimoto CHM, Chao M, Smith SM. Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. Journal of Clinical Oncology. 36: 7504-7504. DOI: 10.1200/Jco.2018.36.15_Suppl.7504  0.493
2018 Sikic BI, Lakhani NJ, Patnaik A, Shah S, Chandana SR, Rasco DW, Colevas AD, O'Rourke TJ, Papadopoulos KP, Fisher GA, Chao M, Agoram B, Chen JY, Huang J, Axt M, et al. A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors. Journal of Clinical Oncology. 36: 3002-3002. DOI: 10.1200/Jco.2018.36.15_Suppl.3002  0.719
2018 Agoram B, Wang B, Sikic BI, Lakhani NJ, Patnaik A, Liu J, Secreto R, Chao M, Takimoto CH. Pharmacokinetics of Hu5F9-G4, a first-in-class anti-CD47 antibody, in patients with solid tumors and lymphomas. Journal of Clinical Oncology. 36: 2525-2525. DOI: 10.1200/Jco.2018.36.15_Suppl.2525  0.567
2016 Chao MP, Gentles AJ, Chatterjee S, Lan F, Reinisch A, Corces MR, Xavy S, Shen J, Haag D, Chanda S, Sinha R, Morganti RM, Nishimura T, Ameen M, Wu H, et al. Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell. PMID 28089908 DOI: 10.1016/J.Stem.2016.11.018  0.687
2016 Weiskopf K, Schnorr PJ, Pang WW, Chao MP, Chhabra A, Seita J, Feng M, Weissman IL. Myeloid Cell Origins, Differentiation, and Clinical Implications. Microbiology Spectrum. 4. PMID 27763252 DOI: 10.1128/Microbiolspec.Mchd-0031-2016  0.552
2015 Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL, Majeti R. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. Plos One. 10: e0137345. PMID 26390038 DOI: 10.1371/Journal.Pone.0137345  0.769
2015 Chu TW, Zhang R, Yang J, Chao MP, Shami PJ, Kopeček J. A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab. Theranostics. 5: 834-46. PMID 26000056 DOI: 10.7150/thno.12040  0.458
2015 Chao MP, Hong J, Kunder C, Lester L, Schrier SL, Majeti R. Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab. American Journal of Hematology. 90: 78-81. PMID 24942207 DOI: 10.1002/Ajh.23791  0.473
2012 Han MH, Lundgren DH, Jaiswal S, Chao M, Graham KL, Garris CS, Axtell RC, Ho PP, Lock CB, Woodard JI, Brownell SE, Zoudilova M, Hunt JF, Baranzini SE, Butcher EC, et al. Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice. The Journal of Experimental Medicine. 209: 1325-34. PMID 22734047 DOI: 10.1084/Jem.20101974  0.606
2012 Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 109: 6662-7. PMID 22451913 DOI: 10.1073/Pnas.1121623109  0.737
2012 Chao MP, Weissman IL, Majeti R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Current Opinion in Immunology. 24: 225-32. PMID 22310103 DOI: 10.1016/J.Coi.2012.01.010  0.643
2012 Chao MP, Majeti R, Weissman IL. Programmed cell removal: a new obstacle in the road to developing cancer. Nature Reviews. Cancer. 12: 58-67. PMID 22158022 DOI: 10.1038/Nrc3171  0.593
2011 Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 118: 4890-901. PMID 21828138 DOI: 10.1182/Blood-2011-02-338020  0.745
2011 Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proceedings of the National Academy of Sciences of the United States of America. 108: 5009-14. PMID 21383193 DOI: 10.1073/Pnas.1100551108  0.738
2011 Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 117: 2423-32. PMID 21193697 DOI: 10.1182/Blood-2010-08-301945  0.537
2011 Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Research. 71: 1374-84. PMID 21177380 DOI: 10.1158/0008-5472.Can-10-2238  0.795
2010 Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Science Translational Medicine. 2: 63ra94. PMID 21178137 DOI: 10.1126/Scitranslmed.3001375  0.726
2010 Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 142: 699-713. PMID 20813259 DOI: 10.1016/J.Cell.2010.07.044  0.788
2010 Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends in Immunology. 31: 212-9. PMID 20452821 DOI: 10.1016/J.It.2010.04.001  0.688
2010 Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Chao M, Chen L, Tedder T, Levy R. Immunomodulation of NK Cells through 4-1BB (CD137) to Improve the Anti-Lymphoma Activity of Rituximab: Antibody-Based Anti-Lymphoma Synergy Blood. 116: 422-422. DOI: 10.1182/Blood.V116.21.422.422  0.6
2010 Chan KS, Volkmer J, Chao M, Shortliffe L, Weissman I. 965 CHARACTERIZATION AND PRECLINICAL TARGETING OF HUMAN BLADDER CANCER STEM CELLS Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1912  0.509
2009 Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J, Chang HY, van de Rijn M, Shortliffe L, Weissman IL. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America. 106: 14016-21. PMID 19666525 DOI: 10.1073/Pnas.0906549106  0.522
2009 Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 138: 286-99. PMID 19632179 DOI: 10.1016/J.Cell.2009.05.045  0.752
2009 Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 138: 271-85. PMID 19632178 DOI: 10.1016/J.Cell.2009.05.046  0.728
2006 Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, Jones C, Zehnder JL, Lilleberg SL, Weissman IL. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proceedings of the National Academy of Sciences of the United States of America. 103: 6224-9. PMID 16603627 DOI: 10.1073/Pnas.0601462103  0.497
2005 Jamieson C, Karimi M, Creusot R, Negrin R, Gotlib J, Chao M, Jones C, Keating A, Fathman CG, Zehnder J, Weissman IL. Bioluminescent Imaging of Human Leukemic Stem Cell Engraftment. Blood. 106: 696-696. DOI: 10.1182/Blood.V106.11.696.696  0.556
2005 Jamieson C, Jaiswal S, Traver D, Gotlib J, Chao M, Weissman IL. Increased Expression of CD47 Is a Constant Marker in Mouse and Human Myeloid Leukemias. Blood. 106: 3260-3260. DOI: 10.1182/Blood.V106.11.3260.3260  0.638
2005 Jamieson CH, Gotlib J, Chao M, Mariappan MR, LayRaj M, Jones C, Zehnder J, Durocher J, Lilleberg S, Coutre S, Weissman IL. Molecular Progenitor Profiling in Human Myeloproliferative Disorders. Blood. 106: 118-118. DOI: 10.1182/Blood.V106.11.118.118  0.493
Show low-probability matches.